BSE Live
Feb 24, 16:01Prev. Close
893.20
Open Price
887.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Feb 24, 15:59Prev. Close
893.00
Open Price
886.90
Bid Price (Qty.)
944.85 (1)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Natco Pharma (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 583.10 | 847.40 | 887.60 | 634.10 | 221.50 | |
| Net CashFlow From Operating Activities | 422.50 | 698.80 | 476.40 | 329.80 | 189.90 | |
| Net Cash Used In Investing Activities | -165.00 | -645.20 | -1,131.10 | -290.60 | -249.30 | |
| Net Cash Used From Financing Activities | -261.10 | -52.20 | 652.00 | -45.60 | 151.40 | |
| Foreign Exchange Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 1.20 | |
| Net Inc/Dec In Cash And Cash Equivalents | -3.60 | 1.40 | -2.70 | -6.40 | 93.20 | |
| Cash And Cash Equivalents Begin of Year | 11.50 | 10.10 | 12.80 | 19.20 | -170.00 | |
| Cash And Cash Equivalents End Of Year | 7.90 | 11.50 | 10.10 | 12.80 | -76.80 |
16.02.2026
Natco Pharma shares rise over 11% after firm receives approval to launch Semaglutide in India
16.02.2026
26.11.2025
Natco Pharma Consolidated September 2025 Net Sales at Rs 1,363.00 crore, down 0.59% Y-o-Y
24.11.2025
Natco Pharma Standalone September 2025 Net Sales at Rs 1,264.30 crore, down 2.19% Y-o-Y
26.11.2025
Natco Pharma Consolidated September 2025 Net Sales at Rs 1,363.00 crore, down 0.59% Y-o-Y
24.11.2025
Natco Pharma Standalone September 2025 Net Sales at Rs 1,264.30 crore, down 2.19% Y-o-Y
14.11.2025
Natco Pharma Consolidated September 2025 Net Sales at Rs 1,363.00 crore, down 0.59% Y-o-Y
09.09.2025
Natco Pharma Standalone June 2025 Net Sales at Rs 1,192.70 crore, down 3.57% Y-o-Y